Journal
DRUG DISCOVERY TODAY
Volume 17, Issue 5-6, Pages 253-260Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2012.02.003
Keywords
-
Categories
Funding
- Cancer Research UK [15678] Funding Source: researchfish
Ask authors/readers for more resources
Vast resources are expended during the development of new cancer therapeutics, and selection of optimal in vivo models should improve this process. Genetically engineered mouse models (GEMM) of cancer have progressively improved in technical sophistication and, accurately recapitulating the human cognate condition, have had a measureable impact on our knowledge of tumourigenesis. However, the application of GEMMs to facilitate the development of innovative therapeutic and diagnostic approaches has lagged behind. GEMMs that recapitulate human cancer offer an additional opportunity to accelerate drug development, and should complement the role of the widely used engraftment tumour models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available